In the slot blot assay, concurrent administration of HGF and NPC-CM (5.18 ± 0.69) as well as HGF-preconditioned NPC-CM (2.56 ± 0.39) yielded a significant reduction in CSPG deposition relative to TGF β1-activated controls (14.37 ± 2.86; p = 0.0405 and p = 0.0045, respectively; Figure 3C). This evidence concerns the gene HGF and nasopharyngeal carcinoma.